A critical characteristic of prostate cancer is the oncogenic activation of the mammalian target of rapamycin (mTOR) pathway, which facilitates the initiation, progression and therapeutic resistance of prostate cancer [127]. This evidence concerns the gene MTOR and prostate cancer.